Your patients deserve early, accurate information on a wide range of serious chromosomal abnormalities—information that only the Panorama prenatal test can provide.

Panorama™ Prenatal Test provides superior coverage
and the highest accuracy of any other prenatal screening test.

The Next Generation in NIPT

Panorama is the only test that uses the advanced science afforded by SNPs to differentiate fetal DNA from maternal DNA and to determine the genotype of the fetus. This allows the Panorama test to report risk scores with extremely high accuracy across all conditions tested.

Other technologies do not separate out the maternal DNA from the fetal DNA—they simply count the total number of chromosomes and compare to a reference chromosome. With these counting or quantitative methods, inconsistent amplification during sequencing can make it difficult to measure the difference between the expected number of chromosomes and the observed number, leading to reduced accuracy.

Watch the video to learn more about the technology behind the Panorama test.

Highest Accuracy of all NIPTs, even at Low Fetal Fractions

With the counting method used by all other NIPTs, accuracy falls when fetal fraction drops below 8%, even for Trisomy 21, which is the easiest trisomy to identify. Other technologies do not report the fetal fraction percentage, so physicians may not know when the accuracy of their patients’ results is impacted by low fetal fraction.

Panorama’s accuracy remains excellent even at fetal fractions as low as 4%, and fetal fraction percentage is always reported.
Table: Low Fetal Fraction Decreases Sensitivity for Counting Technologies

Accurate Results at 9 Weeks Gestational Age

While fetal fraction of DNA in the mother’s blood can vary greatly throughout gestational age, it does tend to be lower earlier in the pregnancy. By using SNP technology, the Panorama test is consistently accurate even at lower fetal fractions, and can be used as early as 9 weeks gestation.

Consistently High Accuracy Across All Chromosomes Evaluated

The Panorama test identifies Trisomy 21, Trisomy 18, Trisomy 13, and Monosomy X.

Comparison of NIPT Performance

Table: Comparison Chart: Panorama

You and your patients deserve the reassurance that comes from having the most accurate and comprehensive genetic screening information.

Clinical Guidelines

According to current American College of Obstetricians and Gynecologists (ACOG) guidelines, a non-invasive prenatal test should be offered as a first-line screening test for patients with an increased risk of fetal aneuploidy.

Clinical indications include:

  • Advanced maternal age
  • Ultrasound indicating increased risk of aneuploidy
  • Abnormal serum screening
  • Prior pregnancy with a trisomy
  • Known parental balanced translocation

Contra-indications:

  • Confirmed multiple-gestation pregnancy
  • Egg donor or surrogacy
  • Bone-marrow transfer recipient
     
References
1. Palomaki GE et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011 Nov; 13(11):913-20.
2. Palomaki GE et al. DNA sequencing of maternal plasma reliably identified trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;3:296-305.
3. Sequenom Internal Data (www.sequenom.com).
4. Bianchi DW et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;5:890-901.
5. Verinata Internal Data (www.Verinata.com).
6. Ashoor et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;doi:10.1016/j.ajog2012.01.029.
7. Nicolaides KH et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first trimester population. Am J Obstet Gynecol 2012;207:1.e1-1.e6.
8. Ashoor G et al. Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound Obstet Gynecol 2013;41:21-25.
9. Ariosa Internal Data (www.ariosa.com).
10. Zimmermann, B., et al.Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat. Diagn, 2012; doi: 10.1002/pd.3993.
11. Samanago-Sprouse C et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn; manuscript under review.
12. Natera Internal Data (www.panoramatest.com).
Panorama™ Prenatal Test is a registered trademark or trademark of Natera, Inc.